The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > REGULATORY
REGULATORY
- Chuikyo Leaning towards Drug Price Revision in October 2019 in Conjunction with Tax Hike
November 1, 2018
- Infection Specialist Proposes to Set Up Vaccination Council within Cabinet Office
October 31, 2018
- Daiichi Sankyo to Use MID-NET Database for Pralia PMS; Second Case from Private Sector
October 31, 2018
- MHLW Council to Discuss Otsuka’s Nalmefene for Treatment of Alcohol Dependency on Nov. 9
October 29, 2018
- ViiV’s HIV Med Juluca Up for MHLW Panel Review on Nov. 8
October 26, 2018
- MHLW to Map Out Additional Step against Rubella Outbreak by Year-End
October 25, 2018
- MHLW Warns against Advertising Claims Suggesting that OTC Cinnamon Bark Products Can Cure Diabetes
October 25, 2018
- AMED Selects 10 More Projects for CiCLE Grant Program, 4 for New Program to Support Startups
October 24, 2018
- MHLW Orders Label Revisions for Lamotrigine to Include Hemophagocytic Syndrome in ADR List
October 24, 2018
- 70% of Wholesalers Have Received Returns of “Opened and Resealed” Drugs: MHLW Survey
October 22, 2018
- MHLW Proposes New Approval Framework Incorporating Conditional OK, Sakigake Scheme
October 19, 2018
- Council Approves MHLW’s Plan to Deal with Difficult-to-Develop Drugs and Indications
October 19, 2018
- PMDA to Focus on Proper Use of Sakigake and Conditional Approval Systems in Its 4th Midterm Plan
October 19, 2018
- Council OKs Public Knowledge-Based Applications for Add’l Pediatric Indications for Blopress
October 19, 2018
- Chuikyo Wary on CEA Use for Reimbursement Decisions as MHLW Sorts Out Discussion Points towards Full Rollout
October 18, 2018
- 3 Pharma Groups Warn against Drug Price Cut in April 2019: Chuikyo
October 18, 2018
- MHLW Lifts Contraindications for Combined Statin-Fibrate Use in Renal-Impaired Patients
October 17, 2018
- ADR Victim Relief Claims Fall below 1,500 in FY2017: MHLW
October 17, 2018
- As Abe Vows to Deliver on Tax Hike Plan, 3 Pharma Groups to Push for October 2019 Price Revision
October 16, 2018
- MEXT Kicks Off “Open Innovation Organization” Initiative, 3 Universities to Push Drug Discovery
October 15, 2018
ページ
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…